Recent findings reveal that immune checkpoint inhibitors (ICIs) significantly improve treatment outcomes for advanced gastric adenocarcinoma (GAC), especially in patients with specific molecular subtypes such as MSI-H and HER2-positive. Combining ICIs with chemotherapy or targeted therapies enhances efficacy, despite the risk of immune-related adverse events (IRAEs). The study emphasizes the need for effective management strategies and future research to identify new therapeutic targets and personalize treatment approaches for improved safety and efficacy in GAC.
Review by Chen Z, Ma Y and Chen J in World J Surg Oncol
© 2025. The Author(s).